. . . . . "98%"@en . . . . "98769-81-4"@en . . "# Fleishaker JC: Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet. 2000 Dec;39(6):413-27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11192474 # Edwards DM, Pellizzoni C, Breuel HP, Berardi A, Castelli MG, Frigerio E, Poggesi I, Rocchetti M, Dubini A, Strolin Benedetti M: Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos. 1995 Aug;16(6):443-60. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7579027 # Wienkers LC, Allievi C, Hauer MJ, Wynalda MA: Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos. 1999 Nov;27(11):1334-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10534319 # Kasper S, el Giamal N, Hilger E: Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11249515 # Fleishaker JC: Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet. 2000 Dec;39(6):413-27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11192474"@en . "(S"@en . . " "@en . . . . . . . "investigational"@en . "Reboxetine is rapidly and extensively absorbed following oral administration."@en . . . . . . . . "S)-Reboxetine"@en . . . "SID11114256"@en . "Reboxetine"@en . "Reboxetine is a selective inhibitor of noradrenaline reuptake. It inhibits noradrenaline reuptake in vitro to a similar extent to the tricyclic antidepressant desmethylimipramine. Reboxetine does not affect dopamine or serotonin reuptake and it has low in vivo and in vitro affinity for adrenergic, cholinergic, histaminergic, dopaminergic and serotonergic receptors."@en . . . "Reboxetine"@en . "Humans and other mammals"@en . . . "For the treatment of clinical depression."@en . . . . . . . "12.5 hours"@en . . . . "Reports of seizures (rare) have been reported"@en . "Esreboxetine"@en . "Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine."@en . . . "approved"@en .